MYL - Insys Therapeutics Is Ready To Change Lanes And Shift Gears In 2019
Insys Therapeutics (INSY) has had an agonizing past two years due to the combination of financial and legal troubles. Federal investigations into the company and former executives have hurt sales, which in turn, has decimated the share price.
However, the sales of its flagship commercial product, SUBSYS, are finding support, and SYNDROS has found a small piece of the market. Regarding the legal troubles, the company believes the worst is behind them as they attempt to separate the 2019 Insys from the former version of the company. The goal of the company is